The purpose of the programme is to provide external quality assessment (EQA), as part of the overall quality assurance, for Direct Thrombin (lla) and Xa inhibitors (DOACs).
Participation is open to health care professionals in all areas of clinical and scientific practice. Participation by industrial and other laboratories is welcomed. Registration is open to laboratories in all countries, whether governement supported, private or commercial.
The participant registered should be the centre responsible for performing the tests. Data from participants will be treated with strict confidentiality. Registered participants will be given a unique participation number, which should be quoted in all correspondance. Use of this number will assist in maintaining confidentiality in survey correspondance.
This programme is currently a paper-based programme. All participants are asked to provide email contact details, as these will be used for alerts about survey distribution and availability of reports. Email addresses alongside other participant information are confidential, and not shared with any third party.
As part of registration, participants in the UK are requested to formally agree to adhere to the Joint Working Group's Conditions of Participation in UK EQA Schemes. With the few exceptions indicated in these Conditions, the Director is obliged to observe strict confidentiality regarding individual performance. All participant details are held in strict confidence and are not shared with any third party. Use of the participant number will assist in maintaining confidentiality in survey correspondance.